Form 4: Indaptus Therapeutics CFO Nir Sassi Acquires 75,000 Stock Options
SEC Form 4 Filing
Nir Sassi, CFO of Indaptus Therapeutics, acquired 75,000 stock options on October 9, 2024, according to a Form 4 filing with the SEC.
Summary
- Nir Sassi, the Chief Financial Officer of Indaptus Therapeutics, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on October 9, 2024.
- Sassi acquired 75,000 stock options with an exercise price of $1.105.
- These options vest fully on April 9, 2026, contingent upon Sassi's continued service to the company.
- Following the transaction, Sassi directly owns 75,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders can monitor insider transactions to assess management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 10/09/2024 | Date of stock option acquisition |
| 04/09/2026 | Stock options vest fully |
| 10/09/2034 | Stock options expiration date |
| 10/10/2024 | Date of Form 4 filing |
Keywords
Form 4, Stock Options, Indaptus Therapeutics, Nir Sassi, CFO, Beneficial Ownership, INDP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.